Latest news with #QuadriaCapital
Mint
2 days ago
- Business
- Mint
HealthQuad to raise $300 million third fund amidst reorganization
HealthQuad, the early to growth stage healthcare-focused investor backed by private equity firm Quadria Capital, is looking to raise its third fund of around $300 million. This new fund comes at a time when there is a split in the general partners (GPs) that manage HealthQuad, people with knowledge of the development said. Also Read | Quadria Capital-backed Maxivision on expansion spree, eyes IPO by 2027 'The firm has refiled its papers with the markets regulator to raise the third fund. The refile shows only Sunil Thakur, Amit Varma and Abrar Mir, the founders of Quadria as the GPs of the firm," one of the persons cited above said. In 2015, when HealthQuad was set up to invest in early-stage healthcare opportunities in India, the three partners had roped in Charles-Antoine Janssen as the fourth founder and appointed him as chief investment officer. 'Now these three founders have taken back control. Janssen is parting ways to start his own fund—HealthKois," the person said. Two top executives at HealthQuad—Pinak Shrikhande and Ajay Mahipal—are also leaving with Janssen. Also Read | Quadria to invest half its India capital in climate-related healthcare solutions HealthQuad and Janssen spokespersons did not respond to emailed queries seeking comments. Mahipal, too, did not respond to messages on LinkedIn. Shrikhande could not be reached for comment. As per Janssen's LinkedIn profile, apart from being associated with HealthQuad, he cofounded KOIS s.a. with François de Borchgrave, a global impact investing firm (blended finance structuring and investment management) active in healthcare, education/skilling and living environments. He is a member of the investment committee of two other KOIS funds: Tara IV (India VC/PE healthcare and social entrepreneurship focus) and Impact Expansion (EU/PE Impact focus). Janssen is based in Belgium. 'The commercials of the first two funds will continue to remain the same. From the third fund onwards, the firm will have only three partners," the second person added. Janssen is likely to launch his firm, which will source deals in the early to growth stage in India. Though the exact strategy is not clear at this point in time. HealthQuad raised its first fund of ₹75 crore in 2016. It has yet to exhaust its second fund, which has a corpus of $162 million. Some of its portfolio companies include the Asian Institute of Nephrology and Urology (AINU), HealthifyMe, Medikabazaar, THB, Impact Guru, Ekincare and Stanplus. The reorganization at HealthQuad comes as the parent company, Quadria Capital, announced the closing of its third fund with $1.07 billion in total commitments. The oversubscribed fundraise comprises over $954 million in primary commitments and $114 million in committed co-investment capital. An additional $300 million co-investment capacity is anticipated over the course of the investment phase, bringing total committed capital to approximately $1.3 billion upon full deployment, Mint reported earlier this week.
Yahoo
4 days ago
- Business
- Yahoo
Quadria Capital closes Fund III fundraising round to advance healthcare at $1.07bn
Singapore-based private equity company Quadria Capital has closed its Fund III fundraising round, which aimed to raise capital to "transform" healthcare across Asia. The fundraising round has secured a total of $1.07bn in commitments and surpassed its original goal of $800m. It is 60% larger than the company's previous fund, which was held in 2020 and raised $600m. The oversubscribed Fund III includes more than $954m in primary commitments and $114m in committed co-investment capital. The total capital pledged is forecast to approach approximately $1.3bn once fully allocated, anticipating a further $300m in co-investment potential during the investment period. Quadria Capital co-founder and managing partner Abrar Mir said: 'Fund III's close, amid one of the most demanding fundraising climates in recent memory, is a powerful validation of our strategy and our mission. 'It reflects deep global investor conviction in the transformational opportunity in Asian Healthcare, where social impact and financial performance go hand in hand.' Quadria Capital has received support from its largest existing backers, which include North American and European sovereign wealth funds, strategic corporates and asset managers. The fund has additionally received pledges from institutional backers and support from the Gulf Cooperation Council (GCC) nations, including Saudi Arabia, the United Arab Emirates and Bahrain. Indian investors, including banks, insurance companies and family offices, have also shown interest and contributed capital. Quadria Capital said the fundraising round positions it for structural growth in Vietnam, where the healthcare market is currently worth $25bn. The company claims its investment in FV Hospital, one of the country's largest healthcare providers, has led to "major clinical improvements and substantial enhancements in patient outcomes". Last year, Quadria Capital was in advanced discussions to acquire a minority stake in NephroPlus, an India-based dialysis chain, for around Rs20bn ($250m). "Quadria Capital closes Fund III fundraising round to advance healthcare at $1.07bn" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
New Indian Express
4 days ago
- Business
- New Indian Express
Quadria's oversubscribed fund: What it signals for Asia's healthcare industry
'It reflects the strong global investor confidence in the transformational opportunity within Asian healthcare, where social impact and financial performance go hand in hand,' confirms Abrar Mir, co-founder and managing partner at Quadria Capital. Quadria Capital said in a statement on Tuesday that Fund III drew support from prominent sovereign wealth funds, asset managers, and strategic corporates across North America and Europe. It also secured new commitments from globally recognised institutional investors, with notable participation from leading institutions in the GCC—including Saudi Arabia, the UAE, and Bahrain. In India, the Fund attracted new capital from major banks, insurance companies, and family offices. Additionally, robust re-up commitments from impact investors reaffirm Quadria's dedication to building scalable, high-impact healthcare businesses that deliver lifesaving care to underserved populations across Asia. Asian Healthcare Scenario Currently Asia's healthcare market is estimated to be $5 trillion, and the healthcare industry is reportedly at a pivotal inflection point and will remain a focal area into 2025. "In India, particularly, we're seeing significant investment interest in single-specialty hospitals, diagnostics, medical devices, and pharmaceutical manufacturing—including active pharma ingredients (APIs) and contract (drug) development and manufacturing (CDM). These segments are poised for growth due to increasing healthcare consumption, cost-efficiency initiatives, and deeper technology integration," says Dr Amit Verma, co-founder and managing partner, Quadria Capital. Healthcare growth funds like Quadria's typically provide the industry with strategic guidance and operational support to help scale their businesses and achieve market leadership. Quadria claims that nearly 40% of Fund III is already deployed. Its current investments include Aragen Life Sciences (a global CRDMO serving 400+ pharmaceutical clients), NephroPlus (Asia's largest dialysis chain), and Maxivision (India's leading eye care chain). Two new investments in Southeast Asia are expected shortly, it says. India Impact India is rapidly emerging as a strategic hub for global pharmaceutical and MedTech manufacturing as supply chains diversify, especially with the China plus strategy. While the per capita healthcare spending in India remains low at just $74—far below regional peers like Thailand (US$364) and Malaysia (US$487)—with nearly 50% of healthcare costs still paid out-of-pocket, the healthcare focused funds can catalyse Indian healthcare innovation by strategically investing in high-growth areas such as specialised care and pharmaceutical manufacturing, aiming to create scalable, affordable healthcare solutions for over a billion people.
&w=3840&q=100)
Business Standard
4 days ago
- Business
- Business Standard
Quadria closes $1.07 bn healthcare fund, seeks growth in India and S Asia
Quadria Capital has closed its Fund III at $1.07 billion after exceeding the target to raise $800 million, said the healthcare-focused private equity (PE) firm on Tuesday. The amount raised includes $954 million in primary commitments and $114 million as co-investment capital. A further $300 million is expected to be raised in co-investments later and the total capital available could reach up to $1.3 billion, said the Singapore-based firm in a statement. The amount raised is almost 60 per cent more from the $600 million the company's second plan got in 2020, making III the largest dedicated healthcare PE fund for South and Southeast Asia. 'Asia's healthcare sector is at a pivotal moment, and it will remain in the limelight in 2025, especially with investment interest in India in areas like single speciality hospitals, diagnostic chains, medical devices, and pharmaceutical manufacturing,' said Amit Varma, cofounder and managing partner at Quadria Capital. The sector will grow because of higher healthcare consumption, 'cost-efficiency initiatives and technology integration', he said. Fund III drew participation from existing investors, who boosted their commitments by an average of 80 per cent, as well as global institutions across North America, Europe, the Middle East, and Asia. New backers included sovereign wealth funds, insurance firms, and family offices, particularly from west Asia and India. Fund III is already nearly 40 per cent deployed, with investments in Aragen Life Sciences, NephroPlus, and Maxivision. Two additional transactions in Southeast Asia are expected to close soon, the company said. Founded in 2012, Quadria manages more than $4 billion in assets across 27 companies. The firm said it plans to build a portfolio of about 10 market-leading healthcare businesses with Fund III, through majority and minority stakes, and co-investments.
Entrepreneur
5 days ago
- Business
- Entrepreneur
Quadria Capital Closes Oversubscribed USD 1 Bn Fund III to Power Asia's Healthcare Future
Quadria's Fund III, 40% deployed, backs Aragen, NephroPlus, and Maxivision, aiming to build a 10-company portfolio delivering scalable, accessible healthcare across Asia through strategic majority and minority investments. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. In a landmark move underscoring global confidence in Asia's healthcare potential, Quadria Capital, a leading healthcare-focused private equity firm, has announced the final close of Fund III with total commitments of USD 1.07 billion, far exceeding its original target of USD 800 million. This marks one of the largest dedicated healthcare PE funds in South and Southeast Asia. The fund attracted over USD 954 million in primary commitments and USD 114 million in co-investment capital, with an additional USD 300 million expected during the investment phase. This brings potential deployable capital to approximately USD 1.3 billion, a substantial 60% increase from Quadria's previous fund in 2020. "Fund III's close, amid one of the most demanding fundraising climates in recent memory, is a powerful validation of our strategy and our mission," said Abrar Mir, Co-founder and Managing Partner of Quadria Capital. "It reflects deep global investor conviction in the transformational opportunity in Asian healthcare, where social impact and financial performance go hand in hand." Quadria's success comes at a time of tightening global capital, highlighting investor belief in its proven strategy and the booming potential of Asia's USD 5 trillion healthcare market. The fund saw strong backing from existing investors, who increased commitments by an average of 80%, and drew in new capital from blue-chip institutions across North America, Europe, the GCC, and Asia, including Indian banks, insurers, and family offices. Dr Amit Varma, Co-founder and Managing Partner, emphasised India's strategic role: "Asia's healthcare sector is at a pivotal moment. We are entering a golden decade of transformation. Our investment philosophy centers on forging deep partnerships with India's healthcare visionaries as the 'partner of choice'." India remains core to Quadria's strategy, with low per capita healthcare spend (USD 74) and growing demand driving innovation and private sector growth. Fund III, already nearly 40% deployed, includes investments in Aragen Life Sciences, NephroPlus, and Maxivision, with more Southeast Asian deals on the horizon. With Fund III, Quadria aims to build a portfolio of 10 high-impact healthcare companies, taking both majority and minority stakes to fuel scalable, accessible care across Asia.
